AU2016276573A1 - Methods of making protein deacetylase inhibitors - Google Patents
Methods of making protein deacetylase inhibitors Download PDFInfo
- Publication number
- AU2016276573A1 AU2016276573A1 AU2016276573A AU2016276573A AU2016276573A1 AU 2016276573 A1 AU2016276573 A1 AU 2016276573A1 AU 2016276573 A AU2016276573 A AU 2016276573A AU 2016276573 A AU2016276573 A AU 2016276573A AU 2016276573 A1 AU2016276573 A1 AU 2016276573A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- pct
- converting
- composition
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZUKQDXJKYIIHBW-UHFFFAOYSA-N CCOC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O Chemical compound CCOC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O ZUKQDXJKYIIHBW-UHFFFAOYSA-N 0.000 description 2
- GFAWPYSWPKUABW-UHFFFAOYSA-N CCN(c1ccccc1)c(nc1)ncc1C(OCC)=C Chemical compound CCN(c1ccccc1)c(nc1)ncc1C(OCC)=C GFAWPYSWPKUABW-UHFFFAOYSA-N 0.000 description 1
- MMYPIVCZGPMEMY-UHFFFAOYSA-N OC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O Chemical compound OC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O MMYPIVCZGPMEMY-UHFFFAOYSA-N 0.000 description 1
- KVCUEYZPPXIXMV-UHFFFAOYSA-N OC(c1cnc(N(c2ccccc2)c2ccccc2Cl)nc1)=O Chemical compound OC(c1cnc(N(c2ccccc2)c2ccccc2Cl)nc1)=O KVCUEYZPPXIXMV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020267299A AU2020267299B2 (en) | 2015-06-08 | 2020-11-13 | Methods of making protein deacetylase inhibitors |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172624P | 2015-06-08 | 2015-06-08 | |
| US62/172,624 | 2015-06-08 | ||
| PCT/US2016/036434 WO2016200930A1 (en) | 2015-06-08 | 2016-06-08 | Methods of making protein deacetylase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020267299A Division AU2020267299B2 (en) | 2015-06-08 | 2020-11-13 | Methods of making protein deacetylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016276573A1 true AU2016276573A1 (en) | 2018-01-04 |
Family
ID=56264043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016276573A Abandoned AU2016276573A1 (en) | 2015-06-08 | 2016-06-08 | Methods of making protein deacetylase inhibitors |
| AU2020267299A Active AU2020267299B2 (en) | 2015-06-08 | 2020-11-13 | Methods of making protein deacetylase inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020267299A Active AU2020267299B2 (en) | 2015-06-08 | 2020-11-13 | Methods of making protein deacetylase inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10144714B2 (OSRAM) |
| EP (1) | EP3303304B1 (OSRAM) |
| JP (1) | JP6873053B2 (OSRAM) |
| CN (1) | CN107922352B (OSRAM) |
| AR (1) | AR105812A1 (OSRAM) |
| AU (2) | AU2016276573A1 (OSRAM) |
| CA (1) | CA2988594C (OSRAM) |
| ES (1) | ES2769255T3 (OSRAM) |
| MX (1) | MX369349B (OSRAM) |
| TW (1) | TWI706937B (OSRAM) |
| WO (1) | WO2016200930A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102933558B (zh) | 2010-01-22 | 2016-03-16 | 埃斯泰隆制药公司 | 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法 |
| WO2013158984A1 (en) | 2012-04-19 | 2013-10-24 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| EP3303306B1 (en) | 2015-06-08 | 2020-02-12 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
| CA2988594C (en) | 2015-06-08 | 2023-08-15 | Acetylon Pharmaceuticals, Inc. | Methods of making protein deacetylase inhibitors |
| EP3468559B1 (en) * | 2016-06-09 | 2023-11-22 | Dana Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors |
| JP7100018B2 (ja) | 2016-08-08 | 2022-07-12 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用 |
| US11497746B2 (en) | 2016-11-23 | 2022-11-15 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| WO2001070675A2 (en) | 2000-03-24 | 2001-09-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2002074298A1 (en) | 2001-03-21 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Il-6 production inhibitors |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| BR0213791A (pt) | 2001-11-01 | 2004-12-07 | Janssen Pharmaceutica Nv | Derivados de amida como inibidores de glicogênio sintase quinase 3-beta |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7381825B2 (en) | 2003-03-17 | 2008-06-03 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2531661C (en) | 2003-07-07 | 2013-03-12 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| US8227636B2 (en) | 2004-04-05 | 2012-07-24 | Merck Hdac Research, Llc | Histone deacetylase inhibitor prodrugs |
| CN101495116A (zh) | 2005-03-22 | 2009-07-29 | 哈佛大学校长及研究员协会 | 蛋白降解病症的治疗 |
| EP1940805A4 (en) | 2005-08-26 | 2009-11-11 | Methylgene Inc | BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE |
| JP5441416B2 (ja) | 2006-02-14 | 2014-03-12 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二官能性ヒストンデアセチラーゼインヒビター |
| CN101484156B (zh) | 2006-05-03 | 2015-11-25 | 哈佛大学校长及研究员协会 | 组蛋白脱乙酰基酶和微管蛋白脱乙酰基酶抑制剂 |
| WO2007144341A1 (en) | 2006-06-12 | 2007-12-21 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
| ES2288802B1 (es) | 2006-07-07 | 2008-12-16 | Universidad De Granada | Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas. |
| WO2008033746A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| EP2255818B1 (en) | 2008-02-19 | 2018-08-22 | Earnest Medicine Co., Ltd. | Oral or enteral composition useful for recovery of physical functions |
| RU2515611C2 (ru) | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
| WO2010131922A2 (en) | 2009-05-15 | 2010-11-18 | Korea Research Institute Of Chemical Technology | Amide compound, preparation method thereof and pharmaceutical composition comprising same |
| US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
| US8551984B2 (en) * | 2009-12-17 | 2013-10-08 | Merck Sharp & Dohme Corp. | Aminopyrimidines as SYK inhibitors |
| US20130040998A1 (en) | 2010-01-08 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Fluorinated hdac inhibitors and uses thereof |
| CN102933558B (zh) | 2010-01-22 | 2016-03-16 | 埃斯泰隆制药公司 | 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法 |
| AU2011255281A1 (en) | 2010-05-21 | 2013-01-10 | Sloan-Kettering Institute For Cancer Research | Selective HDAC inhibitors |
| WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| NZ710405A (en) | 2010-11-16 | 2017-04-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| EP2734500A4 (en) | 2011-07-20 | 2015-04-08 | Gen Hospital Corp | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS |
| EP2760843B1 (en) * | 2011-09-26 | 2016-03-02 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| JP5724851B2 (ja) * | 2011-11-30 | 2015-05-27 | 東レ株式会社 | Ｎ−（ヨードフェニル）ピリミジニルアミン誘導体の製造方法 |
| WO2013158984A1 (en) | 2012-04-19 | 2013-10-24 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| HK1213471A1 (zh) | 2012-10-12 | 2016-07-08 | The Trustees Of The University Of Pennsylvania | 作為蛋白脫乙酰基酶抑制劑的嘧啶羥基酰胺化合物及其使用方法 |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| JP2016511237A (ja) | 2013-02-01 | 2016-04-14 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 選択的ｈｄａｃ３阻害剤 |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| WO2014197471A1 (en) | 2013-06-03 | 2014-12-11 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase ( hdac) biomarkers in multiple myeloma |
| JP2016531163A (ja) | 2013-09-20 | 2016-10-06 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｈｄａｃ６阻害物質を用いた、異常なリンパ球の機能に起因する疾患の治療 |
| ES2929576T3 (es) * | 2013-10-08 | 2022-11-30 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama |
| EP3055299B1 (en) | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| EP3054953B1 (en) | 2013-10-10 | 2020-07-01 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma |
| JP2016536354A (ja) | 2013-10-10 | 2016-11-24 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との組み合わせ |
| EP3054939A4 (en) | 2013-10-11 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deactylase inhibitors and immunomodulatory drugs |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| KR20160092018A (ko) | 2013-12-03 | 2016-08-03 | 에이스틸론 파마수티컬스 인코포레이티드 | 히스톤 탈아세틸화효소 저해제 및 면역조절 약물의 조합 |
| JP7017309B2 (ja) | 2013-12-20 | 2022-02-08 | アセチロン ファーマシューティカルズ インコーポレイテッド | 多発性骨髄腫におけるヒストン脱アセチル化酵素６（ｈｄａｃ６）バイオマーカー |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| US20150359794A1 (en) | 2014-06-13 | 2015-12-17 | Buck Institute For Research On Aging | Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation |
| AU2015288060A1 (en) | 2014-07-07 | 2017-02-09 | Acetylon Pharmaceuticals, Inc. | Treatment of leukemia with histone deacetylase inhibitors |
| EP3204006A4 (en) | 2014-10-08 | 2018-04-04 | Regenacy Pharmaceuticals, LLC | Induction of gata2 by hdac1 and hdac2 inhibitors |
| WO2016090230A1 (en) | 2014-12-05 | 2016-06-09 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds for treating peripheral neuropathy |
| AU2015356779A1 (en) | 2014-12-05 | 2017-07-13 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma |
| US9790180B2 (en) | 2014-12-12 | 2017-10-17 | Regenacy Pharmaceuticals, Llc | Piperidine derivatives as HDAC1/2 inhibitors |
| US20160339022A1 (en) | 2015-04-17 | 2016-11-24 | Acetylon Pharmaceuticals Inc. | Treatment of neuroblastoma with histone deacetylase inhibitors |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| CA2988594C (en) | 2015-06-08 | 2023-08-15 | Acetylon Pharmaceuticals, Inc. | Methods of making protein deacetylase inhibitors |
| EP3303306B1 (en) | 2015-06-08 | 2020-02-12 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
| JP7100018B2 (ja) | 2016-08-08 | 2022-07-12 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用 |
-
2016
- 2016-06-08 CA CA2988594A patent/CA2988594C/en active Active
- 2016-06-08 JP JP2017563541A patent/JP6873053B2/ja active Active
- 2016-06-08 AR ARP160101701A patent/AR105812A1/es unknown
- 2016-06-08 US US15/176,826 patent/US10144714B2/en active Active
- 2016-06-08 WO PCT/US2016/036434 patent/WO2016200930A1/en not_active Ceased
- 2016-06-08 TW TW105118213A patent/TWI706937B/zh active
- 2016-06-08 ES ES16732810T patent/ES2769255T3/es active Active
- 2016-06-08 CN CN201680046553.8A patent/CN107922352B/zh active Active
- 2016-06-08 EP EP16732810.3A patent/EP3303304B1/en active Active
- 2016-06-08 AU AU2016276573A patent/AU2016276573A1/en not_active Abandoned
- 2016-06-08 MX MX2017015900A patent/MX369349B/es active IP Right Grant
-
2020
- 2020-11-13 AU AU2020267299A patent/AU2020267299B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017015900A (es) | 2018-11-09 |
| TW201718517A (zh) | 2017-06-01 |
| WO2016200930A1 (en) | 2016-12-15 |
| ES2769255T3 (es) | 2020-06-25 |
| AU2020267299A1 (en) | 2020-12-10 |
| AU2020267299B2 (en) | 2022-07-07 |
| MX369349B (es) | 2019-11-06 |
| TWI706937B (zh) | 2020-10-11 |
| CN107922352A (zh) | 2018-04-17 |
| AR105812A1 (es) | 2017-11-15 |
| CA2988594C (en) | 2023-08-15 |
| US10144714B2 (en) | 2018-12-04 |
| WO2016200930A9 (en) | 2017-02-23 |
| JP6873053B2 (ja) | 2021-05-19 |
| EP3303304A1 (en) | 2018-04-11 |
| CA2988594A1 (en) | 2016-12-15 |
| CN107922352B (zh) | 2021-08-06 |
| US20160355486A1 (en) | 2016-12-08 |
| EP3303304B1 (en) | 2019-11-20 |
| JP2018518486A (ja) | 2018-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020267299B2 (en) | Methods of making protein deacetylase inhibitors | |
| JP7157752B2 (ja) | Ａｇ－１０、その中間体及びその塩の調製方法 | |
| EP2794610B1 (en) | Processes and intermediates for preparing pralatrexate | |
| WO2014009966A2 (en) | An improved process for the preparation of dabigatran etexilate mesylate and its intermediates thereof | |
| KR102875297B1 (ko) | 화학적 방법 | |
| JP7182562B2 (ja) | ２－（［１，２，３］トリアゾール－２－イル）－安息香酸誘導体の製造 | |
| CA3107270A1 (en) | Method for producing tetracyclic compound | |
| JP2010502567A (ja) | １−（３，４−ジクロロベンジル）−５−オクチルビグアナイドまたはその塩の製造方法 | |
| EP3024821B1 (en) | Process for the preparation of perampanel | |
| JP2013531004A (ja) | トロンビン特異的インヒビターの調製のための中間体及び方法 | |
| AU2011222588B2 (en) | Process for the preparation of 2-(cyclohexylmethyl)-N-{2- [(2S)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide | |
| CN117186018B (zh) | 一种合成海博麦布关键中间体的新方法 | |
| JP7492997B2 (ja) | オラパリブの製造方法 | |
| JP7315805B1 (ja) | 単環ピリジン誘導体の合成中間体の製造方法 | |
| US20120142932A1 (en) | Method for manufacturing 4-(5-methylpyridin-2-ylamino)piperidine-1-carboxylic acid derivative | |
| CA3214107A1 (en) | New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds | |
| WO2023006986A1 (en) | Method for preparing and purifying an agent suitable for treating anemia | |
| KR20160060188A (ko) | 솔리페나신 또는 그 염의 결정형 제조방법, 이에 사용되는 신규 중간체 및 그 제조방법 | |
| KR20190110400A (ko) | 새로운 중간체를 이용한 바제독시펜의 제조방법 | |
| JP2017218411A (ja) | 結晶構造を有する１−（３−カルボキシピリジル−２−）−２−フェニル−４−メチルピペラジン及びその製造方法 | |
| KR20070117381A (ko) | 로사탄의 새로운 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |